Onduo, a Verily-Sanofi joint venture focused on digitally-driven diabetes management, is looking to further protect its members from foot ulcers and limb loss. Orpyx Medical Technologies’ diabetic foot ulcer sensors for its members. Thanks to a newly announced deal struck between the companies, Orpyx Medical Technologies’ FDA-cleared SurroSense Rx system will be available to “select members” of Onduo’s diabetes management program in 2019. The system consists of a thin sensor that is placed in a patient’s shoes and a wirelessly connected smartwatch, which displays readings and alerts to the user when dangerous pressure levels are detected. "Orpyx helps people with diabetes to prevent foot ulcers by providing insight that protects foot health and mobility and reduces the risk of complications that can lead to limb loss," Breanne Everett, CEO of Orpyx Medical Technologies, said in a statement. "We are pleased to extend access to our foot sensor technology to the Onduo member community and to invite Orpyx US patients to take advantage of Onduo services." What’s the impact Onduo’s digital platform is an integrated ecosystem of software and devices designed to provide personalized diabetes management. The addition of Orpyx’s system provides the program’s members with another option for foot ulcer prevention, allowing them to choose the offering that most conveniently fits their comfort and lifestyle. What’s the trend Onduo’s “virtual clinic” has been front and center for a number of partnerships since it launched on a $500 million investment in later 2016. These deals range from partnerships with the Blue Cross Blue Shield Association to a spate of platform integrations with digital diabetes care companies like Voluntus, Glytec and BioTelemetry. That said, the program does have its competitors. Vida Health, WellDoc, Livongo and Glooko are all offering or building similar platforms focused on comprehensive diabetes management using digital tools. On the record "Managing diabetes is a 24/7 job and we want to make access to care and monitoring easier for members," Dr. Josh Riff, CEO of Onduo, said in a statement. "We are thrilled to partner with Orpyx to help keep members walking and living actively in our community."
Verily - Sanofi joint venture Onduo has signed a deal with GE Healthcare Technologies to offer the latter firm 's SurroSense Rx system to select users of Onduo ’s personalised diabetes management platform in 2019 . Orpyx 's SurroSense Rx system comprises a thin sensor , which is placed inside a patient 's shoe , and sends an alert to a connected smartwatch if it detects dangerous pressure levels .